SEBI halts proposed slump sale pending independent valuation
PAR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.4 pts more than Nifty Microcap 250 and 4.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
SEBI's 15 September 2025 interim order stopped Par Drugs and Chemicals from proceeding with the 14 February 2025 sale of its business undertaking to Phal-Jig Fine Chemicals. NSE must appoint an independent valuer, and the company must not transfer the related assets until further directions. The company reported no quantified financial or operational impact as of 16 September 2025.
The proposed sale is on hold, delaying the transaction and creating regulatory uncertainty. The company says there is no quantified financial or operational impact so far.